This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
What's New in Psoriatic Arthritis—Clinical Considerations When Targeting Specific Pathways

What's New in Psoriatic Arthritis—Clinical Considerations When Targeting Specific Pathways

Format

Webcast

Time to Complete

1 hour

Released

January 17, 2017

Expires

January 17, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Lilly USA, LLC.

Program Description

The goals of this clinical and critical-thinking webcast are to help clinicians improve their abilities to properly assess psoriatic arthritis (PsA) using Classification Criteria for Psoriatic Arthritis (CASPAR) and review the current standard of care and emerging agents, considering their mechanisms of action and targets for treatment.

Intended Audience

Rheumatologists, nurse practitioners (NPs), physician assistants (PAs), and other clinicians who provide care for, manage, or refer patients with PsA (eg, podiatrists)

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Incorporate validated diagnostic criteria, disease-activity measures, and clinical guidelines into clinical practice for early detection and intervention in psoriatic arthritis (PsA)
  • Perform a comprehensive assessment of PsA, disease progression, response to treatment, and comorbidities that is considerate of each patient’s disease severity and impact on quality of life
  • Employ evidence-based recommendations and more recent clinical trial experiences to develop individualized treatment regimens for patients across the spectrum of PsA severity
  • Assess the mechanisms, efficacy, safety, tolerability, and ease of use of emerging medications for achieving treatment goals in patients with PsA

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

M. Elaine Husni, MD, MPH
Assistant Professor of Medicine, CCLCM
Vice Chair, Department of Rheumatic and Immunologic Disease
Director, Arthritis & Musculoskeletal Center
Orthopedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Dr. Husni reports that she receives consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and Regeneron.

Ana-Maria Orbai, MD, MHS
Assistant Professor of Medicine
Director, Psoriatic Arthritis Program
Johns Hopkins Arthritis Center
Baltimore, MD

Dr. Orbai reports that she receives consulting fees from Janssen. Dr. Orbai has conducted contracted research supported by Celgene, Lilly, and Janssen.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Lilly USA, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cmequestions@haymarketmedical.com.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue